HLA-C and psoriasis: A meta-analysis of eight studies including 1048 psoriasis patients showed that HLA-C*06:02 positive patients had a median PASI75 response rate of 92% after 6 months of ustekinumab therapy compared to a median PASI75 response rate of 67% in the HLA-C*06:02 negative patients (11).